Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Smoking by Pregnant Teens Trends Upward Again

January 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

HYATTSVILLE, Md-The number of teenagers who smoke while pregnant is on the rise again. Data from a new National Center for Health Statistics (NCHS) study show that smoking among pregnant women between the ages of 15 and 19 increased to 17.2% in 1995 and 1996 after declining for several years. Non-Hispanic whites, at 29%, had the highest rate of smoking among pregnant teenagers. The study found a significant decline overall in smoking by pregnant women, from almost 20% in 1990 to 14% in 1996.

HYATTSVILLE, Md—The number of teenagers who smoke while pregnant is on the rise again. Data from a new National Center for Health Statistics (NCHS) study show that smoking among pregnant women between the ages of 15 and 19 increased to 17.2% in 1995 and 1996 after declining for several years. Non-Hispanic whites, at 29%, had the highest rate of smoking among pregnant teenagers. The study found a significant decline overall in smoking by pregnant women, from almost 20% in 1990 to 14% in 1996.

Articles in this issue

Pittsburgh to Build New Cancer Center
NCI Initiates Two High-Priority Tobacco Research Programs
Breast Cancer Stamp Sells Well
Hospital Strategies To Prevent Invasive Aspergillosis Spread
‘Cancer Patients Should Be Assertive, Know Their Rights’
EBCTCG Update of Adjuvant Treatment for Early Breast Cancer
Younger Breast Cancer Patients at Increased Risk of Recurrence
Six Named to National Cancer Advisory Board
Trial Uses Vitamin A To Prevent Lung Cancer in Former Smokers
‘Medical School Curriculum Must Include Palliative Care’
Formation of Fibrin Clots Key to Angiogenesis
Some AIDS Experts Now Question ‘Hit Hard, Hit Early’ Strategy
M.D. Anderson Opens New Facility-‘Hospital for the Future’
Transplant Center Uses Cooperative Care Model
High School Seniors Smoking Less in 1998
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.

XTR008 Significantly Extends Progression-Free Survival in SSTR+ GEP-NETs

Sabrina Serani
October 18th 2025
Article

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer

Silas Inman
October 18th 2025
Article

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Jax DiEugenio
October 18th 2025
Article

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.


Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Chris Ryan
October 18th 2025
Article

Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.

Related Content
Advertisement

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.

XTR008 Significantly Extends Progression-Free Survival in SSTR+ GEP-NETs

Sabrina Serani
October 18th 2025
Article

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer

Silas Inman
October 18th 2025
Article

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Jax DiEugenio
October 18th 2025
Article

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.


Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Chris Ryan
October 18th 2025
Article

Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.